Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 762

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 762
---
 The effective interest rate includes cash flow projections for future royalty and milestone payments, which are sensitive to certain assumptions, including market size, market penetration and sales price, that are forward looking and could be affected by future market conditions. During the three and nine months ended September 30, 2024, $694 and $1,989, respectively, were repaid to HCR under the HCR Agreement.

F-17

TABLE OF CONTENTS

CARA THERAPEUTICS, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
(unaudited) The following table summarizes the activity of the HCR Agreement (in thousands):

| ​ | Royalty purchase and sale agreement balance at December 31, 2023      | ​ | ​ | ​ | $ | 37,079 | ​ | ​ |
| ​ | Payments                                                              | ​ | ​ | ​ | ​ | -1,989 | ​ | ​ |
| ​ | Non-cash interest expense                                             | ​ | ​ | ​ | ​ |  5,852 | ​ | ​ |
| ​ | October 1st payment included in accounts payable and accrued expenses | ​ | ​ | ​ | ​ |   -359 | ​ | ​ |
| ​ | Balance at September 30, 2024                                         | ​ | ​ | ​ | $ | 40,583 | ​ | ​ |
| ​ | Effective interest rate                                               | ​ | ​ | ​ | ​ | 20.90% | ​ | ​ |

11. Stockholders’ Equity On June 7, 2024, the Company filed a Certificate of Amendment to its Certificate of Incorporation, or the Certificate, with the Secretary of State of the State of Delaware, which the Company’s stockholders approved at the Company’s Annual Meeting of Stockholders on June 4, 2024. The Certificate increased the authorized number of shares of common stock of the Company from 8,333,333 shares to 16,666,667 shares. The additional shares of common stock authorized by the Certificate have rights identical to the currently outstanding common stock of the Company and any issuance of common stock authorized by the Certificate would not affect the rights of the holders of currently outstanding common stock of the Company, except for effects incidental to increasing the number of shares of the Company’s common stock outstanding, such as dilution of the earnings per share and voting rights of current holders of common stock. As of September 30